Review Article
Curcumin and obesity
Peter G. Bradford,
Corresponding Author
Peter G. Bradford
Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY
+. Tel.: +716-829-2110. Fax: +716-829-2801.
Ph.D., Department of Pharmacology & Toxicology, 102 Farber Hall, State University of New York at Buffalo, Buffalo, NY 14214-3000 USASearch for more papers by this author
Peter G. Bradford,
Corresponding Author
Peter G. Bradford
Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY
+. Tel.: +716-829-2110. Fax: +716-829-2801.
Ph.D., Department of Pharmacology & Toxicology, 102 Farber Hall, State University of New York at Buffalo, Buffalo, NY 14214-3000 USASearch for more papers by this authorAbstract
Turmeric has been long recognized for its anti-inflammatory and health-promoting properties. Curcumin is one of the principal anti-inflammatory and healthful components of turmeric comprising 2–8% of most turmeric preparations. Experimental evidence supports the activity of curcumin in promoting weight loss and reducing the incidence of obesity-related diseases. With the discovery that obesity is characterized by chronic low-grade metabolic inflammation, phytochemicals like curcumin which have anti-inflammatory activity are being intensely investigated. Recent scientific research reveals that curcumin directly interacts with white adipose tissue to suppress chronic inflammation. In adipose tissue, curcumin inhibits macrophage infiltration and nuclear factor κB (NF-κB) activation induced by inflammatory agents. Curcumin reduces the expression of the potent proinflammatory adipokines tumor necrosis factor-α (TNFα), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator inhibitor type-1 (PAI-1), and it induces the expression of adiponectin, the principal anti-inflammatory agent secreted by adipocytes. Curcumin also has effects to inhibit adipocyte differentiation and to promote antioxidant activities. Through these diverse mechanisms curcumin reduces obesity and curtails the adverse health effects of obesity. © 2013 BioFactors, 39(1):78–87, 2013
References
- 1 Turmeric Rice Recipe http://www.food.com/recipe/tuermeric-rice-48162.
- 2 Hamdy, O., Citkowitz, E., Uwaifo, G. I., and Arioglu, E., (2012) Obesity http://emedicine.medscape.com/article/123702.
- 3 Aggarwal, B. B. ( 2010) Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu. Rev. Nutr. 30, 173–199.
- 4 World Health Organization. (2012) Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/index.html.
- 5 Caroll, M. D., Kit, B. K., Ogden, C. L., and Flegal K.M. ( 2012) Prevalence of obesity and trends in the distribution of body mass index among us adults, 1999–2010. JAMA 307, 491–497.
- 6 Graubard, B. I., Williamson, D. F., Gail, M. H., and Flegal K.M. ( 2005) Excess deaths associated with underweight, overweight, and obesity. JAMA 293, 1861–1867.
- 7 Berrington de Gonzale, A., Hartge, P., Cerhan, J. R., Flint, A. J., Hannan, L., et al. ( 2010) Body-mass index and mortality among 1.46 million white adults. N. Engl. J. Med. 363, 2211–2219.
- 8 Reilly, J. J. and Kelly, J. ( 2011) Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review. Int. J. Obes. (Lond) 35, 891–898.
- 9 International Association for the Study of Obesity. (2010) www.iaso.org/policy/healthimpactobesity/estimatesrelativerisk/.
- 10 Collaboration, P. S. ( 2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373, 1083–1096.
- 11 Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., et al. ( 2009) The incidence of co-morbidities related to obesity and overweight: a systemic review and meta-analysis. BMC Public Health 9, 88.
- 12 Balagopal, P. B., de Ferranti, S. D., Cook, S., Daniels, S. R., Gidding, S. S., et al. ( 2011) Nontraditional risk factors and biomarkers for cardiovascular disease: mechanistic, research, and clinical considerations for youth: a scientific statement from the American Heart Association. Circulation 123, 2749–2769.
- 13 Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., et al. ( 2011) Heart Disease and Stroke Statistics—2011 update. Circulation 123, e18–e209.
- 14 Muntner, P., He, J., Chen, J., Fonseca, V., and Whelton, P. K. ( 2004) Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann. Epidemiol. 14, 686–695.
- 15 Mauras, N., DelGiorno, C., Kollman, C., Bird, K., Morgan, M., et al. ( 2010) Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J. Clin. Endocr. Metab. 95, 1060–1068.
- 16 Tzotzas, T., Evangelou, P., and Kiortsis, D. N. ( 2011) Obesity, weight loss and conditional cardiovascular risk factors. Obes. Rev. 12, e282–289.
- 17 Tzanavari, T., Giannogonas, P., and Karalis, K. P. ( 2010) TNF-alpha and obesity. Curr. Dir. Autoimmun. 11, 145–156.
- 18 Ibrahim, M. M. ( 2010) Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 11, 11–18.
- 19 Zimmet, P., Alberti, K. G., and Shaw, J. ( 2001) Global and societal implications of the diabetes epidemic. Nature 414, 782–787.
- 20 Colagiuri, S. ( 2010) Diabesity: therapeutic options. Diabetes Obes. Metab. 12, 463–473.
- 21 Bays, H., Mandarino, L., and DeFronzo, R. A. ( 2004) Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 89, 463–478.
- 22 Wagenknecht, L. E., Langefeld, C. D., Scherzinger, A. L., Norris, J. M., Haffner, S. M., et al. ( 2003) Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes 52, 2490–2496.
- 23 Runhaar, J., Koes, B. W., Clockaerts, S., and Bierma-Zeinstra, S. M. A. ( 2011) A systematic review on changed biomechanics of lower extremities in obese individuals: a possible role in development of osteoarthritis. Obes. Rev. 12, 1071–1082.
- 24 Iannone, F. and Lapadula, G. ( 2010) Obesity and inflammation—targets for OA therapy. Curr. Drug Targets 11, 586–598.
- 25 Goldring, M. B. and Otero, M. ( 2011) Inflammation in osteoarthritis. Curr. Opin. Rheumatol. 23, 471–478.
- 26 Clockaerts, S., Bastiaansen-Jenniskens, Y. M., Runhaar, J., Van Osch, G. J. V. M., Van Offel, J. F., et al. ( 2010) The infrapatellar fat pad should be considered as an active osteoarthritic joint tissue: a narrative review. Osteoarthritis Cartilage 18, 876–882.
- 27 Schaffler, A., Ehling, A., Neumann, E., Herfarth, H., Tarner, I., et al. ( 2003) Adipocytokines in synovial fluid. JAMA 290, 1709–1710.
- 28 Ku, J. H., Lee, C. K., Joo, B. S., An, B. M., Choi, S. H., et al. ( 2009) Correlation of synovial fluid leptin concentrations with the severity of osteoarthritis. Clin. Rheumatol. 28, 1431–1435.
- 29 Henrotin, Y., Clutterbuck, A. L., Allaway, D., Lodwig, E. M., Harris, P., et al. ( 2010) Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage 18, 141–149.
- 30 Goralski, K. B. and Sinal, C.J. ( 2010) Adipose tissue as endocrine organ. In: Adipose Tissue and Inflammation ( A. B Awad. and P.G. Bradford, eds.). pp. 23–45, CRC Press Taylor & Francis Group, Boca Raton.
- 31 Lehr, S., Hartwig, S., Lamers, D., Famulla, S., Müller, S., et al. ( 2012) Identification and validation of novel adipokines released from primary human adipocytes. Mol. Cell. Proteom. 11, M111.010504.
- 32 Conde, J., Scotece, M., Gomez, R., Lopez, V., Gomez-Reino, J. J., et al. ( 2011) Adipokines: biofactors from white adipose tissue. a complex hub among inflammation, metabolism, and immunity. Biofactors 37, 413–420.
- 33 Ouchi, N., Parker, J. L., Lugus, J. J., and Walsh, K. ( 2011) Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85–97.
- 34 Tilg, H., Moschen, A.R. ( 2010) Inflammatory and anti-inflammatory mediators secreted by adipose tissue. In: Adipose Tissue and Inflammation. ( A. B. Awad and P.G. Bradford, eds.). pp. 65–81, CRC Press Taylor & Francis Group, Boca Raton.
- 35 Castan-laurell, I., Dray, C., Knauf, C., Kunduzova, O., and Valet, P. ( 2012) Apelin, a promising target for type 2 diabetes treatment? Trends Endocrinol. Metab. 23, 234–241.
- 36 Wellen, K. E. and Hotamisligil, G. S. ( 2003) Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112, 1785–1788.
- 37 Olefsky, J. M. and Glass, C. K. ( 2010) Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219–246.
- 38 Calder, P. C., Ahluwalia, N., Brouns, F., Buetler, T., Clement, K., et al. ( 2011) Dietary factors and low-grade inflammation in relation to overweight and obesity. Br. J. Nutr. 106 ( Suppl 3): S5–S78.
- 39 Shoelson, S. E., Lee, J., and Goldfine, A. B. ( 2006) Inflammation and insulin resistance. J. Clin. Invest. 116, 1793–1801.
- 40 Hotamisligil, G. S., Shargill, N. S., and Spiegelman, B. M. ( 1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87–91.
- 41 Hotamisligil, G. S. ( 2005) Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 54 ( Suppl 2): S73–S78.
- 42 Bastard, J. P., Maachi, M., Lagathu, C., Kim, M. J., Caron, M., et al. ( 2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17, 4–12.
- 43 Bennett, N. B., Ogston, C. M., McAndrew, G. M., and Ogston, D. ( 1966) Studies on the fibrinolytic enzyme system in obesity. J. Clin. Pathol. 19, 241–243.
- 44 Kruithof, E. K. O. ( 2008) Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb. Haemost. 100, 969–975.
- 45 Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., et al. ( 2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179–188.
- 46 Shah, A., Mehta, N., and Reilly, M. P. ( 2008) Adipose inflammation, insulin resistance, and cardiovascular disease. J. Parenter. Enteral. Nutr. 32, 638–644.
- 47 Suganami, T. and Ogawa, Y. ( 2010) Adipose tissue macrophages: their role in adipose tissue remodeling. J. Leukoc. Biol. 88, 33–39.
- 48 Yang, H., Youm, Y.-H., Vandanmagsar, B., Ravussin, A., Gimble, J. M., et al. ( 2010) Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J. Immunol. 185, 1836–1845.
- 49 Hocking, S. L., Wu, L. E., Guilhaus, M., Chisholm, D. J., and James, D. E. ( 2010) Intrinsic depot-specific differences in the secretome of adipose tissue, preadipocytes, and adipose tissue–derived microvascular endothelial cells. Diabetes 59, 3008–3016.
- 50 Fain, J. N., Madan, A. K., Hiler, M. L., Cheema, P., and Bahouth, S. W. ( 2004) Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145, 2273–2282.
- 51 Arner, E., Rydén, M., and Arner, P. ( 2010) Tumor necrosis factor α and regulation of adipose tissue. N Eng. J. Med. 362, 1151–1153.
- 52 Trayhurn, P. and Wood, I. S. ( 2005) Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem. Soc. Trans. 33, 1078–1081.
- 53 Maury, E. and Brichard, S. M. ( 2010) Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol. Cell. Endocrinol. 314, 1–16.
- 54 Berg, A. H. and Scherer, P. E. ( 2005) Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96, 939–949.
- 55 Horng, T. and Hotamisligil, G. S. ( 2011) Linking the inflammasome to obesity-related disease. Nat. Med. 17, 164–165.
- 56 Zhou, R., Tardivel, A., Thorens, B., Choi, I., and Tschopp, J. ( 2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136–140.
- 57 Gillum, M. P., Kotas, M. E., Erion, D. M., Kursawe, R., Chatterjee, P., et al. ( 2011) SirT1 regulates adipose tissue inflammation. Diabetes 60, 3235–3245.
- 58 Chen, G., Shaw, M. H., Kim, Y.-G., and Nunez, G. ( 2009) NOD-like receptors: role in innate immunity and inflammatory disease. Annu. Rev. Pathol. 4, 365–398.
- 59 Stienstra, R., Tack, C. J., Kanneganti, T. D., Joosten, L. A. B., and Netea, M. G. ( 2012) The inflammasome puts obesity in the danger zone. Cell. Metab. 15, 10–18.
- 60 Goossens, G. H., Blaak, E. E., Theunissen, R., Duijvestijn, A. M., Clément, K., et al. ( 2012) Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol. Immunol. 50, 142–149.
- 61 Zhao, L., Lee, J. Y., and Hwang, D. H. ( 2011) Inhibition of pattern recognition receptor-mediated inflammation by bioactive phytochemicals. Nutr. Rev. 69, 310–320.
- 62 Wagner, R. N., Proell, M., Kufer, T. A., and Schwarzenbacher, R. ( 2009) Evaluation of nod-like receptor (NLR) effector domain interactions. PLoS One 4, e4931.
- 63 Weisberg, S. P., Leibel, R., and Tortoriello, D. V. ( 2008) Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 149, 3549–3558.
- 64 Alappat, L. and Awad, A. B. ( 2010) Curcumin and obesity: evidence and mechanisms. Nutr. Rev. 68, 729–738.
- 65 Shao, W., Yu, Z., Chiang, Y., Yang, Y., Chai, T., et al. ( 2012) Curcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytes. PLoS One 7, e28784.
- 66 Matchanickal Resmi, A., Rafi Mohamed, M. ( 2006) Curcumin: potential health benefits, molecular mechanisms of action, and its anticancer properties in vitro and in vivo. In: Herbs: Challenges in Chemistry and Biology. pp 92–107, American Chemical Society, Washington DC.
10.1021/bk-2006-0925.ch007 Google Scholar
- 67 Shehzad, A., Ha, T., Subhan, F., and Lee, Y. S. ( 2011) New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur. J. Nutr. 50, 151–161.
- 68 Yekollu, S. K., Thomas, R., and O'Sullivan, B. ( 2011) Targeting curcusomes to inflammatory dendritic cells inhibits NF-kappaB and improves insulin resistance in obese mice. Diabetes 60, 2928–2938.
- 69 Costa, G., Francisco, V., Lopes, M. C., Cruz, M. T., and Batista, M. T. ( 2012) Intracellular signaling pathways modulated by phenolic compounds: application for new anti-inflammatory drugs discovery. Curr. Med. Chem. 19, 2876–2900.
- 70 Woo, H.-M., Kang, J.-H., Kawada, T., Yoo, H., Sung, M.-K., et al. ( 2007) Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci. 80, 926–931.
- 71 Olivera, A., Moore, T. W., Hu, F., Brown, A. P., Sun, A., et al. ( 2012) Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int. Immunopharmacol. 12, 368–377.
- 72 Ahn, J., Lee, H., Kim, S., and Ha, T. ( 2010) Curcumin-induced suppression of adipogenic differentiation is accompanied by activation of Wnt/beta-catenin signaling. Am. J. Physiol. Cell. Physiol. 298, C1510–C1516.
- 73 Zhao, J., Sun, X.-B., Ye, F., and Tian, W.-X. ( 2011) Suppression of fatty acid synthase, differentiation and lipid accumulation in adipocytes by curcumin. Mol. Cell. Biochem. 351, 19–28.
- 74 Kim, C. Y., Le, T. T., Chen, C., Cheng, J.-X., and Kim, K.-H. ( 2011) Curcumin inhibits adipocyte differentiation through modulation of mitotic clonal expansion. J. Nutr. Biochem. 22, 910–920.
- 75 Ejaz, A., Wu, D., Kwan, P., and Meydani, M. ( 2009) Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr. 139, 919–925.
- 76 Lee, Y. K., Lee, W. S., Hwang, J. T., Kwon, D. Y., Surh, Y. J., et al. ( 2008) Curcumin exerts antidifferentiation effect through AMPKα-PPAR-γ in 3T3-L1 adipocytes and antiproliferatory effect through AMPKα-COX-2 in cancer cells. J. Agric. Food Chem. 57, 305–310.
- 77 Ross, S. E., Hemati, N., Longo, K. A., Bennett, C. N., Lucas, P. C., et al. ( 2000) Inhibition of adipogenesis by Wnt signaling. Science (New York, N Y) 289, 950–953.
- 78 Bennett, C. N., Ross, S. E., Longo, K. A., Bajnok, L., Hemati, N., et al. ( 2002) Regulation of Wnt signaling during adipogenesis. J. Biol. Chem. 277, 30998–31004.
- 79 Christodoulides, C., Lagathu, C., Sethi, J. K., and Vidal-Puig, A. ( 2009) Adipogenesis and WNT signalling. Trends Endocrinol. Metab. 20, 16–24.
- 80 Ling, L., Nurcombe, V., and Cool, S. M. ( 2009) Wnt signaling controls the fate of mesenchymal stem cells. Gene 433, 1–7.
- 81 Wend, P., Wend, K., Krum, S. A., and Miranda-Carboni, G. A. ( 2012) The role of WNT10B in physiology and disease. Acta Physiol. (Oxford, England) 204, 34–51.
- 82 Rosen, E. D., Hsu, C. H., Wang, X., Sakai, S., Freeman, M. W., et al. ( 2002) C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev. 16, 22–26.
- 83 Jaiswal, A. S., Marlow, B. P., Gupta, N., and Narayan, S. ( 2002) Beta-catenin-mediated transactivation and cell–cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21, 8414–8427.
- 84 Sundram, V., Chauhan, S. C., Ebeling, M., and Jaggi, M. ( 2012) Curcumin attenuates beta-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS One 7, e35368.
- 85 Clevers, H. and Nusse, R. ( 2012) Wnt/β-catenin signaling and disease. Cell 149, 1192–1205.
- 86 Schulte, D. M., Müller, N., Neumann, K., Oberhäuser, F., Faust, M., et al. ( 2012) Pro-inflammatory Wnt5a and anti-inflammatory sFRP5 are differentially regulated by nutritional factors in obese human subjects. PLoS One 7, e32437.
- 87 Sporn, M. B. and Liby, K. T. ( 2012) NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12, 564–571.
- 88 Zhao, S.-G., Li, Q., Liu, Z.-X. Wang, J.-J., Wang, X.-X., et al. ( 2011) Curcumin attenuates insulin resistance in hepatocytes by inducing Nrf2 nuclear translocation. Hepatogastroenterology 58, 2106–2111.
- 89 Magesh, S., Chen, Y., and Hu, L. ( 2012) Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med. Res. Rev. 32, 687–726.
- 90 Pi, J., Leung, L., Xue, P., Wang, W., Hou, Y., et al. ( 2010) Deficiency in the nuclear factor E2-related factor-2 transcription factor results in impaired adipogenesis and protects against diet-induced obesity. J. Biol. Chem. 285, 9292–9300.
- 91 Slomko, H., Heo, H. J., and Einstein, F. H. ( 2012) Minireview: epigenetics of obesity and diabetes in humans. Endocrinology 153, 1025–1030.
- 92 Fu, S. and Kurzrock, R. ( 2010) Development of curcumin as an epigenetic agent. Cancer 116, 4670–4676.
- 93 Khor, T. O., Huang, Y., Wu, T.-Y., Shu, L., Lee, J., et al. ( 2011) Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem. Pharmacol. 82, 1073–1078.
- 94 Chung, S., Yao, H., Caito, S., Hwang, J.-W., Arunachalam, G., et al. ( 2010) Regulation of SIRT1 in cellular functions: Role of polyphenols. Arch. Biochem. Biophys. 501, 79–90.
- 95 Lomb, D. J., Laurent, G., and Haigis, M. C. ( 2010) Sirtuins regulate key aspects of lipid metabolism. Biochim. Biophys. Acta 1804, 1652–1657.
- 96 Dai, H., Kustigian, L., Carney, D., Case, A., Considine, T., et al. ( 2010) SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J. Biol. Chem. 285, 32695–32703.
- 97 Chalkiadaki, A. and Guarente, L. ( 2012) High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell. Metab. 16, 180–188.
- 98 Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., et al. ( 2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450, 712–716.
- 99 Ruderman, N. B., Xu, X. J., Nelson, L., Cacicedo, J. M., Saha, A. K., et al. ( 2010) AMPK and SIRT1: a long-standing partnership? Am. J. Physiol. Endocrinol. Metab. 298, E751–E760.
- 100 Sharma, S., Zhuang, Y., Ying, Z., Wu, A., and Gomez-Pinilla, F. ( 2009) Dietary curcumin supplementation counteracts reduction in levels of molecules involved in energy homeostasis after brain trauma. Neuroscience 161, 1037–1044.
- 101 Na, L. X., Zhang, Y. L., Li, Y., Liu, L. Y., Li, R., et al. ( 2011) Curcumin improves insulin resistance in skeletal muscle of rats. Nutr. Metab. Cardiovasc. Dis. 21, 526–533.
- 102 de Haan, J. B. ( 2011) Nrf2 activators as attractive therapeutics for diabetic nephropathy. Diabetes 60, 2683–2684.
Citing Literature
